This year’s World Health Day, we face unprecedented health disparities and overwhelming grief on a global scale, wrought by the COVID-19 pandemic. From every corner of the world, nations and...
The grant program invites applications from HIV-focused community-based organizations in the Asia Pacific region for funding of innovation projects. Research-based biopharmaceutical company, Gilead...
Pulse survey conducted by Gilead Sciences found that majority of people living with HIV, individuals at risk and HIV care prescribers in Asia Pacific experienced disruptions in HIV care during the...
Gilead Sciences announced in November 2019 the recipients of its 2019 Gilead Asia Pacific Rainbow Grant Programme. The research-based bio-pharmaceutical company, Gilead Sciences, announced in...
Exploring the drug reimbursement scheme in Taiwan to provide increased access to pharmaceutical treatments for Taiwanese patients. In 2017 alone Taiwan’s National Health Expenditure accounted for...
Approval of HIV medication by Taiwan National Health Insurance Administration sets Taiwan on track for the 90-90-90 targets set by UNAIDS. Biktarvy® is a once-daily single table regiment or the...
CryoEM reveals structural effect of mutation that made humans, but not apes, immune to SIV. The simian immunodeficiency virus (SIV) has plagued monkeys and apes for centuries, and it still devastates...
Why is it so difficult to treat HIV? Will there ever be a cure for HIV? by Cal Cohen The human immunodeficiency virus (HIV) infection has come a long way since the disease was first presented in the...
Chinese researchers say further work is necessary before clinical trials are possible. Chinese scientists have identified a new protein that restricts HIV infection, a discovery that could pave the...
In clinical trials, biktarvy demonstrated high efficacy and zero resistance through 48 weeks. The Singapore Health Sciences Authority has approved Gilead Sciences’ Biktarvy, a once-daily single...
